Pertuzumab Dosing in Neoadjuvant HER2-Positive Breast Cancer

Standard Neoadjuvant Regimen

• The National Comprehensive Cancer Network recommends paclitaxel weekly or every 3 weeks (Category 2A recommendation) as a taxane option for neoadjuvant treatment of HER2-positive breast cancer 1
• The National Comprehensive Cancer Network suggests docetaxel 75 mg/m² every 3 weeks (Category 1 recommendation) as a taxane option for neoadjuvant treatment of HER2-positive breast cancer 1, 2

Evidence Supporting This Approach

• The NeoSphere trial demonstrated that pertuzumab-trastuzumab-docetaxel achieved a pathological complete response (pCR) rate of 39.3% versus 21.5% with trastuzumab-docetaxel alone, representing a 16.8% absolute increase in pCR 2

Critical Safety Considerations

• The National Comprehensive Cancer Network advises against administering pertuzumab and trastuzumab concurrently with anthracyclines due to a 27% risk of significant cardiac dysfunction 1, 2

Patient Selection Criteria

• The National Comprehensive Cancer Network guidelines indicate that pertuzumab can be administered to patients with T2 or N1, HER2-positive early-stage breast cancer 1

Post-Neoadjuvant Management

• The National Comprehensive Cancer Network recommends continuing trastuzumab alone to complete 1 year total HER2-targeted therapy after surgery if pertuzumab was given neoadjuvantly 1